News

Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Panic has been setting in

Not for the first time this year, Horizon Technology Finance (NASDAQ: HRZN) is tapping the public markets for a fresh round of capital-raising. Investors clearly didn't consider that to be good

Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. The drugmaker's stock is trending higher despite every major U.S. stock index

Shares of the metabolic disease specialist Viking Therapeutics (NASDAQ: VKTX) were up by 6.6% on slightly below-average volume as of 1:56 p.m. ET Wednesday afternoon. The biotech's stock is heating

While many investors set a retirement goal of $1 million or more, there are many factors that will impact the amount you ultimately have set away for your later years. The length of time you spend

Weight-loss drugs have been surging in popularity over the past year. Even Novo Nordisk's Ozempic, which isn't approved to treat weight loss, has made for a hot trend on social media, with people

CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the

If your stock portfolio hasn't fully recovered from the 2022 bear market, you're definitely not alone. Even after the fairly strong rally in growth and value stocks during the first half of 2023

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had

AT&T (NYSE: T) stock is an alluring option for income investors thanks to its robust dividend, which at current share prices yields nearly 7%. Despite this -- and the company's position as one of

Investors looking for growth stocks that can make dramatic moves in a short time should look more closely at healthcare. Two stocks in this sector have already doubled this year and could climb much

Pfizer (NYSE: PFE) brought in enormous levels of revenue over the past couple of years thanks to its coronavirus vaccine and treatment. The company also continues to benefit from sales of

The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Plenty of stocks are trading

Price is sometimes an indicator of quality, whether on equity markets or elsewhere. But just because a stock has a low sticker price doesn't mean it isn't worth considering. Investors can find

The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. But even in this environment

With savvy stock-picking and a bit of patience, building wealth isn't as difficult as it is often made out to be. This is because quality businesses grow their revenue and profits, which makes their

In many cases, analysts are guilty of being overly optimistic about the near-term prospects of the stocks they cover. But sometimes they err in a completely opposite way.

Vertex Pharmaceuticals

If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long

You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects.

Three Fool.com contributors identified no-brainer healthcare stocks

Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's